Breast Cancer — Microlearning Activity 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates

Research To Practice | Oncology Videos · Dec 5, 2025 · 13m

Featuring an interview with Dr Priyanka Sharma, including the following topics:

Endocrine therapy for hormone receptor-positive, HER2-negative high-risk localized breast cancer (0:00)

Johnston SR et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). ESMO 2025;Abstract LBA13.

Durvalumab in combination with neoadjuvant chemotherapy for localized triple-negative breast cancer (TNBC) (3:25)

Loibl S et al. Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast…